Literature DB >> 29082516

Efficacy of biological agents in the treatment of Erdheim-Chester disease.

Gaurav Goyal1, Mithun V Shah1, Timothy G Call1, Mark R Litzow1, Alexandra P Wolanskyj-Spinner1, Matthew J Koster2, W Oliver Tobin3, Robert Vassallo4, Jay H Ryu4, Christopher C Hook1, William J Hogan1, Ronald S Go1.   

Abstract

Entities:  

Keywords:  Erdheim-Chester disease; etanercept; infliximab; interleukin 1 receptor antagonist protein; treatment outcome

Mesh：

Substances：

Year:  2017        PMID： 29082516     DOI： 10.1111/bjh.14997

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

Review 1.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

Review 2.  Erdheim-Chester Disease: a Concise Review.

Authors:  Matthias Papo; Jean-François Emile; Thiago Trovati Maciel; Pierre Bay; Alistair Baber; Olivier Hermine; Zahir Amoura; Julien Haroche
Journal:  Curr Rheumatol Rep       Date:  2019-12-05       Impact factor: 4.592

3.  Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Authors:  Fréderic Franconieri; Samuel Deshayes; Hubert de Boysson; Salim Trad; Nicolas Martin Silva; Benjamin Terrier; Boris Bienvenu; Françoise Galateau-Sallé; Jean-François Emile; Alison C Johnson; Achille Aouba
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

4.  Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.

Authors:  Xin-Xin Cao; Na Niu; Jian Sun; Hao Cai; Feng-Dan Wang; Yi-Ning Wang; Ming-Hui Duan; Dao-Bin Zhou; Jian Li
Journal:  Orphanet J Rare Dis       Date:  2019-01-10       Impact factor: 4.123

5.  Erdheim-Chester disease: a rare cause of bilateral renal artery stenosis, mimicking large vessel vasculitis.

Authors:  Priyanka Mayur Lakhani; Catherine Borysiewicz; Justin Mason
Journal:  BMJ Case Rep       Date:  2022-03-15

6.  Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis.

Authors:  Ting Liu; Hua-Cong Cai; Hao Cai; Miao Chen; Wei Zhang; Jian Li; Dao-Bin Zhou; Xin-Xin Cao
Journal:  Orphanet J Rare Dis       Date:  2022-02-07       Impact factor: 4.123
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.